Molecular Determinants for the Tissue Specificity of SERMs

Selective estrogen receptor modulators (SERMs) mimic estrogen action in certain tissues while opposing it in others. The therapeutic effectiveness of SERMs such as tamoxifen and raloxifene in breast cancer depends on their antiestrogenic activity. In the uterus, however, tamoxifen is estrogenic. Here, we show that both tamoxifen and raloxifene induce the recruitment of corepressors to target gene promoters in mammary cells. In endometrial cells, tamoxifen, but not raloxifene, acts like estrogen by stimulating the recruitment of coactivators to a subset of genes. The estrogen-like activity of tamoxifen in the uterus requires a high level of steroid receptor coactivator 1 (SRC-1) expression. Thus cell type– and promoter-specific differences in coregulator recruitment determine the cellular response to SERMs.

[1]  Y. Yamasaki,et al.  Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. , 1994, The Journal of biological chemistry.

[2]  F. Miralles,et al.  Characterization of the proximal estrogen-responsive element of human cathepsin D gene. , 1994, Molecular endocrinology.

[3]  J. Williams,et al.  Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer. , 1999, Experimental and molecular pathology.

[4]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[5]  H. Moch,et al.  Tissue microarrays for gene amplification surveys in many different tumor types. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  V. Giguère,et al.  Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. , 1999, Molecular cell.

[7]  S. Gapstur,et al.  Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. , 2001, Journal of the National Cancer Institute.

[8]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[9]  G. Martin,et al.  Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. , 1994, Science.

[10]  M. Tzukerman,et al.  Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. , 1994, Molecular endocrinology.

[11]  P. Chambon,et al.  Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.

[12]  K. Horwitz,et al.  The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. , 1997, Molecular endocrinology.

[13]  P. Chambon,et al.  Promoter specificity of the two transcriptional activation functions of the human oestrogen receptor in yeast. , 1992, Nucleic acids research.

[14]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[15]  S. Inoue,et al.  Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen. , 2001, Biochemical and biophysical research communications.

[16]  R. Evans,et al.  HATs on and beyond chromatin. , 2001, Current opinion in cell biology.

[17]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[18]  L. Freedman,et al.  Nuclear receptor cofactors as chromatin remodelers. , 1999, Current opinion in genetics & development.

[19]  R. Shiu,et al.  Mechanism of estrogen activation of c-myc oncogene expression. , 1992, Oncogene.

[20]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[21]  S. Inoue,et al.  Isolation of Estrogen-Responsive Genes with a CpG Island Library , 1998, Molecular and Cellular Biology.

[22]  L. Soucek,et al.  Making decisions through Myc , 2001, FEBS letters.

[23]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[24]  B. Katzenellenbogen,et al.  Estrogen receptor activation function 1 works by binding p160 coactivator proteins. , 1998, Molecular endocrinology.

[25]  M. Lazar,et al.  Transcriptional Repression by Nuclear Hormone Receptors , 2000, Trends in Endocrinology & Metabolism.

[26]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.